Pre-operative Administration of Sorafenib in Patients With Metastatic Renal Cell Carcinoma Undergoing Kidney Removal

PHASE2CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

October 31, 2012

Study Completion Date

March 31, 2013

Conditions
Renal Cell CarcinomaMetastatic Disease
Interventions
DRUG

Sorafenib

Starting dose: 400 mg (2x200mg tablets) BID (total= 800mg/day) taken orally. The dose can be adjusted as per investigator if required due to toxicity (ex. 200mg BID, 200mg QD). Study drug is taken for 12 weeks preoperatively. Patients restart on study drug 6 weeks postoperatively and continue until progression or unacceptable toxicity occurs.

Trial Locations (1)

M5G 2M9

Princess Margaret Hospital, University Health Network, Toronto

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Bayer

INDUSTRY

lead

University Health Network, Toronto

OTHER